INVO Fertility, Inc. (IVF) P/E Ratio History
Deep ValueTrading at -0.0x · 0th percentile of 5-year range · Significant discount to historical valuation · Data 2010–2010
Loading P/E history...
P/E Ratio Analysis
As of June 30, 2026, INVO Fertility, Inc. (IVF) trades at a price-to-earnings ratio of -0.0x, with a stock price of $1.90 and trailing twelve-month earnings per share of $-7.00.
The current P/E is 100% below its 5-year average of 18215.0x. Over the past five years, IVF's P/E has ranged from a low of 15839.1x to a high of 20590.9x, placing the current valuation at the 0th percentile of its historical range.
Compared to the Healthcare sector median P/E of 22.9x, IVF trades at a 100% discount to its sector peers. The sector includes 231 companies with P/E ratios ranging from 0.0x to 186.2x.
Relative to the broader market, IVF trades at a notable discount to the S&P 500 median P/E of 25.1x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our IVF DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
IVF Cross-Benchmark Valuation
How does the current P/E compare to sector peers and the broader market?
IVF P/E vs Peers
Device suppliers, distribution, and services peers sorted by market cap
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $2B | 44.4 | 6.62 | +14% | |
| $926M | 10.2Lowest | 1.03Best | -36% | |
| $17B | 30.5 | - | -25% | |
| $23B | 26.8 | - | +18%Best | |
| $23B | 24.2 | - | +14% |
Lower P/E can signal a discount or weaker growth expectations; PEG adds growth context.
IVF Historical P/E Data (2010–2010)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Period End | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2010 Q4 | Dec 31 2010 | $12288.00 | $0.78 | 15839.1x | -13% |
| FY2010 Q3 | - | $15974.40 | $0.78 | 20590.9x | +13% |
Average P/E for displayed period: 18215.0x
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
16+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
IVF — Frequently Asked Questions
Quick answers to the most common questions about buying IVF stock.
What is IVF's P/E ratio?
INVO Fertility, Inc. (IVF) trailing twelve-month P/E ratio is -0.0x, based on TTM diluted EPS of $-7.00. The 5-year average P/E is 18215.0x and the historical range spans 15839.1x to 20590.9x.
Is IVF stock overvalued or undervalued?
IVF current P/E: -0.0x. 5-year average P/E: 18215.0x. Percentile: 0th.
Is IVF stock expensive?
IVF is fairly valued relative to its own history. The current P/E of -0.0x is near the 5-year average of 18215.0x (0th percentile of historical range).
What is IVF's historical P/E range?
Over the past 5 years, IVF's P/E ratio has ranged from 15839.1x to 20590.9x, with a median of 20590.9x and an average of 18215.0x. The current P/E of -0.0x places the stock at the 0th percentile of this range. Full historical data spans 2010–2010.
How does IVF's P/E compare to the S&P 500?
IVF current P/E: -0.0x. S&P 500 median P/E: 25.1x.
How does IVF's valuation compare to Healthcare peers?
INVO Fertility, Inc. P/E of -0.0x can be benchmarked against Healthcare peers in the comparison table on this page.
What is IVF's PEG ratio?
IVF PEG ratio is N/A, based on a P/E of -0.0x and EPS growth of 69.9%. PEG normalises P/E by growth and helps compare stocks with different earnings trajectories.
What is IVF's earnings yield?
IVF earnings yield is N/A, the inverse of its -0.0x P/E ratio. Earnings yield represents the percentage of each dollar invested that the company earns. It can be compared directly to bond yields to assess relative attractiveness of stocks versus fixed income.